Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Vomiting 1Nausea 1Glioma 1

Interventions

Temozolomide 610Radiotherapy 387Bevacizumab 253Magnetic Resonance Spectroscopy 202Cyclophosphamide 177Carboplatin 159Radiosurgery 145Etoposide 132Radiation 120Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 81Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × rolapitant × CNS × Clear all
NCT02991456 2023-07-11

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

Duke University

Phase 2 Completed
48 enrolled 25 charts
CNS

Glioma, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡